Tetranor PGDM analyses for the amyotrophic lateral sclerosis: Positive and simple diagnosis and evaluation of drug effect

Biochemical and Biophysical Research Communications

Volumn 415, Issue 4, 2011, Pages 539-544

  Shinozawa, Takao ^a   Urade, Yoshihiro ^b   Maruyama, Toshihiko ^b   Watabe, Daishi ^c  

^a Environmental Biotechnology Institute   (Japan)

^b OSAKA BIOSCIENCE INSTITUTE   (Japan)

^c SAITAMA INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Amyotrophic lateral sclerosis (ALS); Creatinine; Diagnosis; Radicut (edaravone); Tetranor PGDM

Indexed keywords

11,15 DIOXO 9 HYDROXY 2,3,4,5 TETRANORPROSTAN 1,20 DIOIC ACID; BIOLOGICAL MARKER; CREATININE; DRUG METABOLITE; PROSTAGLANDIN D2 DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DRUG EFFECT; HUMAN; MALE; PRIORITY JOURNAL; RESPIRATORY FAILURE;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; BIOMARKERS, PHARMACOLOGICAL; CREATINE; HUMANS; MALE; MIDDLE AGED; PROSTAGLANDIN D2; URINALYSIS;

EID: 84855865037     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.10.045     Document Type: Article

References (24)

1. Julien J.P. Amyotrophic lateral sclerosis. Unfolding the toxicity of the misfolded. Cell 2001, 104:581-591.
2. Van Damme P., Robberecht W. Recent advances in motor neuron disease. Curr. Opin. Neurol. 2009, 22:486-492.
3. Rosen D.R. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 364:362.
4. Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., Reaume A.G., Scott R.W., Cleveland D.W. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998, 281:1851-1854.
5. Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., Price D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995, 14:1105-1116.
6. Sargsyan S.A., Blackburn D.J., Barber S.C., Monk P.N., Shaw P.J. Mutant SOD1 G93A microglia have an inflammatory phenotype and elevated production of MCP-1. Neuroreport 2009, 20:1450-1455.
7. Miller R.G., Mitchell J.D., Lyon M., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph. Lateral Scler. Other. Motor Neuron Disord. 2003, 4:191-206.
8. Aggarwal S., Cudkowicz M. ALS drug development: reflections from the past and a way forward. Neurotherapeutics 2008, 5:516-527.
9. Turner M.R., Kiernan M.C., Leigh P.N., Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009, 8:94-109.
10. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
11. Mohri I., Aritake K., Taniguchi H., Sato Y., Kamauchi S., Nagata N., Maruyama T., Taniike M., Urade Y. Inhibition of prostaglandin D synthase suppresses muscular necrosis. Am. J. Pathol. 2009, 174:1735-1744.
12. Liang X., Wang Q., Shi J., Lokteva L., Breyer R.M., Montine T.J., Andreasson K. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann. Neurol. 2008, 64:304-314.
13. Ilzecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol. Scand. 2003, 108:125-129.
14. Song W.L., Wang M., Ricciotti E., Fries S., Yu Y., Grosser T., Reilly M., Lawson J.A., FitzGerald G.A. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J. Biol. Chem. 2008, 283:1179-1188.
15. Brosnan J.T., Brosnan M.E. Creatine: endogenous metabolite, dietary, and therapeutic supplement. Annu. Rev. Nutr. 2007, 27:241-261.
16. Franciotta D., Zanardi M.C., Albertotti L., Orcesi S., Berardinelli A., Pichiecchio A., Uggetti C., Tagliabue A. Measurement of skeletal muscle mass in Duchenne muscular dystrophy: use of 24-h creatinine excretion. Acta Diabetol. 2003, 40(Suppl. 1):S290-292.
17. Ito H., Wate R., Zhang J., Ohnishi S., Kaneko S., Ito H., Nakano S., Kusaka H. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp. Neurol. 2008, 213:448-455.
18. D'Arrigo A., Colavito D., Pena-Altamira E., Fabris M., Dam M., Contestabile A., Leon A. Transcriptional profiling in the lumbar spinal cord of a mouse model of amyotrophic lateral sclerosis: a role for wild-type superoxide dismutase 1 in sporadic disease?. J. Mol. Neurosci. 2010, 41:404-415.
19. Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H., Komure O., Matsuura S., Kobatake K., Morimoto N., Abe K., Suzuki N., Aoki M., Kawata A., Hirai T., Kato T., Ogasawara K., Hirano A., Takumi T., Kusaka H., Hagiwara K., Kaji R., Kawakami H. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 465:223-226.
20. McGeer P.L., McGeer E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002, 26:459-470.
21. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
22. Wu L., Wang Q., Liang X., Andreasson K. Divergent effects of prostaglandin receptor signaling on neuronal survival. Neurosci. Lett. 2007, 421:253-258.
23. Bilak M., Wu L., Wang Q., Haughey N., Conant K., St Hillaire C., Andreasson K. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann. Neurol. 2004, 56:240-248.
24. Consilvio C., Vincent A.M., Feldman E.L. Neuroinflammation, COX-2, and ALS - a dual role?. Exp. Neurol. 2004, 187:1-10.